REQUIP ropinirole
Refer to the “Also Known As” section to reference different products that include the same medication as REQUIP.
Drug Basics
Brand Name: REQUIP
Generic Name: ROPINIROLE
Drug Type: HUMAN PRESCRIPTION DRUG
Route: ORAL
Dosage Form: TABLET, FILM COATED
Data Current As Of: 2019-03-11
indications & usage
parkinson’s disease
REQUIP is indicated for the treatment of Parkinson’s disease.
restless legs syndrome
REQUIP is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
drug interactions
cytochrome p450 1a2 inhibitors & inducers
In vitro metabolism studies showed that cytochrome P450 1A2 (CYP1A2) is the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with REQUIP, adjustment of the dose of REQUIP may be required. Coadministration of ciprofloxacin, an inhibitor of CYP1A2, increases the AUC and Cmax of ropinirole [see Clinical Pharmacology (12.3)]. Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking [see Clinical Pharmacology (12.3)].
estrogens
Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy) reduced the clearance of ropinirole. Starting or stopping hormone replacement therapy may require adjustment of dosage of REQUIP [see Clinical Pharmacology (12.3)].
dopamine antagonists
Because ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (e.g., phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may reduce the efficacy of REQUIP.
patient counseling information
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Dosing Instructions
Instruct patients to take REQUIP only as prescribed. If a dose is missed, advise patients not to double their next dose. REQUIP can be taken with or without food [see Dosage and Administration (2.1)].
Ropinirole is the active ingredient in both REQUIP XL and REQUIP tablets (the immediate‑release formulation). Ask your patients if they are taking another medication containing ropinirole.
Hypersensitivity/Allergic Reactions
Advise patients about the potential for developing a hypersensitivity/allergic reaction including manifestations such as urticaria, angioedema, rash, and pruritus when taking any ropinirole product. Inform patients who experience these or similar reactions to immediately contact their healthcare professional [see Contraindications (4)].
Falling Asleep during Activities of Daily Living and Somnolence
Alert patients to the potential sedating effects caused by REQUIP, including somnolence and the possibility of falling asleep while engaged in activities of daily living. Because somnolence is a frequent adverse reaction with potentially serious consequences, patients should not drive a car, operate machinery, or engage in other potentially dangerous activities until they have gained sufficient experience with REQUIP to gauge whether or not it adversely affects their mental and/or motor performance. Advise patients that if increased somnolence or episodes of falling asleep during activities of daily living (e.g., conversations, eating, driving a motor vehicle) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician.
Advise patients of possible additive effects when patients are taking other sedating medications, alcohol, or other central nervous system depressants (e.g., benzodiazepines, antipsychotics, antidepressants) in combination with REQUIP or when taking a concomitant medication (e.g., ciprofloxacin) that increases plasma levels of ropinirole [see Warnings and Precautions (5.1)].
Syncope and Hypotension/Orthostatic Hypotension
Advise patients that they may experience syncope and may develop hypotension with or without symptoms such as dizziness, nausea, syncope, and sometimes sweating while taking REQUIP, especially if they are elderly. Hypotension and/or orthostatic symptoms may occur more frequently during initial therapy or with an increase in dose at any time (cases have been seen after weeks of treatment). Postural/orthostatic symptoms may be related to sitting up or standing. Accordingly, caution patients against standing rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with REQUIP [see Warnings and Precautions (5.2, 5.3)].
Hallucinations/Psychotic-Like Behavior
Inform patients that they may experience hallucinations (unreal visions, sounds, or sensations), and that other psychotic-like behavior can occur while taking REQUIP. The elderly are at greater risk than younger patients with Parkinson’s disease. This risk is greater in patients who are taking REQUIP with L-dopa or taking higher doses of REQUIP and may also be further increased in patients taking any other drugs that increase dopaminergic tone. Tell patients to report hallucinations or psychotic-like behavior to their healthcare provider promptly should they develop [see Warnings and Precautions (5.4)].
Dyskinesia
Inform patients that REQUIP may cause and/or exacerbate pre-existing dyskinesias [see Warnings and Precautions (5.5)].
Impulse Control/Compulsive Behaviors
Advise patients that they may experience impulse control and/or compulsive behaviors while taking 1 or more of the medications (including REQUIP) that increase central dopaminergic tone, that are generally used for the treatment of Parkinson’s disease. Advise patients to inform their physician or healthcare provider if they develop new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with REQUIP. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking REQUIP [see Warnings and Precautions (5.6)].
Withdrawal-Emergent Hyperpyrexia and Confusion
Advise patients to contact their healthcare provider if they wish to discontinue REQUIP or decrease the dose of REQUIP [see Warnings and Precautions (5.7)].
Melanoma
Advise patients with Parkinson’s disease that they have a higher risk of developing melanoma. Advise patients to have their skin examined on a regular basis by a qualified healthcare provider (e.g., dermatologist) when using REQUIP for any indication [see Warnings and Precautions (5.8)].
Augmentation and Rebound
Inform patients with RLS that augmentation and/or rebound may occur after starting treatment with REQUIP [see Warnings and Precautions (5.9)].
Nursing Mothers
Because of the possibility that ropinirole may be excreted in breast milk, discuss the developmental and health benefits of breastfeeding along with the mother’s clinical need for REQUIP and any potential adverse effects on the breastfed child from ropinirole or from the underlying maternal condition [see Use in Specific Populations (8.2)]. Advise patients that REQUIP could inhibit lactation because ropinirole inhibits prolactin secretion.
Pregnancy
Because experience with ropinirole in pregnant women is limited and ropinirole has been shown to have adverse effects on embryofetal development in animals, including teratogenic effects, advise patients of this potential risk. Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy [see Use in Specific Populations (8.1)].
Trademarks are owned by or licensed to the GSK group of companies.
GlaxoSmithKline
Research Triangle Park, NC 27709
©2018 GSK group of companies or its licensor.
REP:7PI
PATIENT INFORMATION | |||
REQUIP (RE-qwip) (ropinirole) tablets | REQUIP XL (RE-qwip) (ropinirole) extended-release tablets | ||
If you have Parkinson’s disease, read this side. If you have Restless Legs Syndrome (RLS), read the other side. Important Note: REQUIP XL has not been studied in RLS and is not approved for the treatment of RLS. However, an immediate-release form of ropinirole (REQUIP) is approved for the treatment of moderate to severe primary RLS (see other side of this leaflet). | |||
What is the most important information I should know about REQUIP and REQUIP XL? REQUIP and REQUIP XL can cause serious side effects, including:
| |||
What are REQUIP and REQUIP XL?
Having one of these conditions does not mean you have or will develop the other condition. You should not be taking more than 1 medicine containing ropinirole. Tell your healthcare provider if you are taking any other medicine containing ropinirole. It is not known if REQUIP and REQUIP XL are safe and effective for use in children younger than 18 years of age. | |||
Do not take REQUIP or REQUIP XL if you:
| |||
|
| ||
|
| ||
Before taking REQUIP or REQUIP XL, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of these medicines may increase your chances of getting side effects while taking REQUIP or REQUIP XL. | |||
How should I take REQUIP or REQUIP XL?
If you are taking REQUIP:
If you are taking REQUIP XL:
| |||
What are the possible side effects of REQUIP and REQUIP XL? REQUIP and REQUIP XL can cause serious side effects, including:
The most common side effects of REQUIP and REQUIP XL include: | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all of the possible side effects with REQUIP and REQUIP XL. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||
How should I store REQUIP or REQUIP XL?
Keep REQUIP or REQUIP XL and all medicines out of the reach of children. | |||
General information about the safe and effective use of REQUIP or REQUIP XL. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use REQUIP or REQUIP XL for a condition for which it was not prescribed. Do not give REQUIP or REQUIP XL to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about REQUIP or REQUIP XL that is written for health professionals. | |||
What are the ingredients in REQUIP and REQUIP XL? The following ingredients are in REQUIP: Active ingredient: ropinirole (as ropinirole hydrochloride) Inactive ingredients: croscarmellose sodium, hydrous lactose, magnesium stearate, microcrystalline cellulose, and one or more of the following: carmine, FD&C Blue No. 2 aluminum lake, FD&C Yellow No. 6 aluminum lake, hypromellose, iron oxides, polyethylene glycol, polysorbate 80, titanium dioxide. The following ingredients are in REQUIP XL: Active ingredient: ropinirole (as ropinirole hydrochloride) Inactive ingredients: carboxymethylcellulose sodium, colloidal silicon dioxide, glycerol behenate, hydrogenated castor oil, hypromellose, lactose monohydrate, magnesium stearate, maltodextrin, mannitol, povidone, and one or more of the following: FD&C Yellow No. 6 aluminum lake, FD&C Blue No.2 aluminum lake, ferric oxides (black, red, yellow), polyethylene glycol 400, titanium dioxide. |
PATIENT INFORMATION | |
REQUIP (RE-qwip) (ropinirole) tablets | |
If you have Restless Legs Syndrome (RLS), read this side. If you have Parkinson’s disease, read the other side. Important Note: REQUIP XL has not been studied in RLS and is not approved for the treatment of RLS. | |
People with RLS should take REQUIP differently than people with Parkinson’s disease (see “How should I take REQUIP for RLS?” for the recommended dosing for RLS). A lower dose of REQUIP is generally needed for people with RLS, and is taken once daily before bedtime. | |
What is the most important information I should know about REQUIP? REQUIP can cause serious side effects, including:
| |
What is REQUIP? REQUIP is a prescription medicine containing ropinirole used to treat moderate-to-severe primary RLS. It is also used to treat Parkinson’s disease. Having one of these conditions does not mean you have or will develop the other condition. You should not be taking more than 1 medicine containing ropinirole. Tell your healthcare provider if you are taking any other medicine containing ropinirole. It is not known if REQUIP is safe and effective for use in children younger than 18 years of age. | |
Do not take REQUIP if you:
| |
|
|
|
|
Before taking REQUIP, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of these medicines may increase your chances of getting side effects while taking REQUIP. | |
How should I take REQUIP?
| |
What are the possible side effects of REQUIP? REQUIP can cause serious side effects, including:
The most common side effects of REQUIP include: | |
|
|
|
|
Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all of the possible side effects with REQUIP. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |
How should I store REQUIP?
Keep REQUIP and all medicines out of the reach of children. | |
General information about the safe and effective use of REQUIP. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use REQUIP for a condition for which it was not prescribed. Do not give REQUIP to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about REQUIP that is written for health professionals. | |
What are the ingredients in REQUIP? Active ingredient: ropinirole (as ropinirole hydrochloride) Inactive ingredients: croscarmellose sodium, hydrous lactose, magnesium stearate, microcrystalline cellulose, and one or more of the following: carmine, FD&C Blue No. 2 aluminum lake, FD&C Yellow No. 6 aluminum lake, hypromellose, iron oxides, polyethylene glycol, polysorbate 80, titanium dioxide. | |
For more information go to www.gsk.com or call 1-888-825-5249 (toll-free). Trademarks are owned by or licensed to the GSK group of companies. GlaxoSmithKline, Research Triangle Park, NC 27709 ©2018 GSK group of companies or its licensor. REP:6PIL | |
This Patient Information has been approved by the U.S. Food and Drug Administration Revised: February 2018 |
PRINCIPAL DISPLAY PANEL
NDC 0007-4890-20
REQUIP®
(rOPINIRole tablets)
0.25 mg
100 Tablets
Rx only
Each tablet contains 0.29 mg ropinirole HCl equivalent to 0.25 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 12/16
10000000143764
PRINCIPAL DISPLAY PANEL
NDC 0007-4891-20
REQUIP®
(rOPINIRole tablets)
0.5 mg
100 Tablets
Rx only
Each tablet contains 0.57 mg ropinirole HCl equivalent to 0.5 mg ropinirole.
Store at controlled room temperature 20o to 25oC (68o to 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 11/16
10000000143765
PRINCIPAL DISPLAY PANEL
NDC 0007-4892-20
REQUIP®
(rOPINIRole tablets)
1 mg
100 Tablets
Rx only
Each tablet contains 1.14 mg ropinirole HCl equivalent to 1 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev.12/16
10000000143769
PRINCIPAL DISPLAY PANEL
NDC 0007-4893-20
REQUIP®
(rOPINIRole tablets)
2 mg
100 Tablets
Rx only
Each tablet contains 2.28 mg ropinirole HCl equivalent to 2 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 11/16
10000000143770
PRINCIPAL DISPLAY PANEL
NDC 0007-4895-20
REQUIP®
(rOPINIRole tablets)
3 mg
100 Tablets
Rx only
Each tablet contains 3.42 mg ropinirole HCl equivalent to 3 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 12/16
10000000143767
PRINCIPAL DISPLAY PANEL
NDC 0007-4896-20
REQUIP®
(rOPINIRole tablets)
4 mg
100 Tablets
Rx only
Each tablet contains 4.56 mg ropinirole HCl equivalent to 4 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 1/17
10000000143766
PRINCIPAL DISPLAY PANEL
NDC 0007-4894-20
REQUIP®
(rOPINIRole tablets)
5 mg
100 Tablets
Rx only
Each tablet contains 5.70 mg ropinirole HCl equivalent to 5 mg ropinirole.
Store at controlled room temperature 20o - 25oC (68o - 77oF) [see USP].
Do not accept if seal on bottle opening is missing or broken.
Protect from light and moisture. Close container tightly after each use.
Dosage: See Prescribing Information for complete dosing instructions.
GlaxoSmithKline
Research Triangle Park,
NC 27709
Made in Ireland
Rev. 11/16
10000000143768
also known as
Or Browse by Name
At Healthgrades, our Editorial Team works hard to develop complete, objective and meaningful health information to help people choose the right doctor, right hospital and right care. Our writers include physicians, pharmacists, and registered nurses with firsthand clinical experience. All condition, treatment and wellness content is medically reviewed by at least one medical professional ensuring the most accurate information possible. Learn more about our editorial process.